Clinical Trial: A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants

U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07454291) titled 'A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants' on March 02.

Brief Summary: The purposes of this study are to:

1. evaluate potential interactions between taladegib (ENV-101) and current standard-of-care (SOC) therapies for idiopathic pulmonary fibrosis (IPF), including nintedanib and pirfenidone, and

2. more fully characterize the pharmacokinetics (PK) of taladegib (i.e., how the body absorbs, distributes, metabolizes and excretes taladegib).

This study will enroll 4 cohorts (groups) of participants. Each cohort will experience a different duratio...